EPISODE TWO

YARAL Pharma, Inc., which launched in 2022, is the U.S. generics subsidiary of IBSA, a long-standing, fully integrated, multinational pharmaceutical company headquartered in Lugano, Switzerland. Yaral is committed to providing high-quality products across a range of therapeutic areas, ensuring continuity of supply, and offering affordable authorized generics and complex generic medicines. In this episode, we focus on IBSA’s innovative patch and Softgel technologies and how YARAL Pharma leverages this technology, aiming to reshape the landscape of patient care and pharmaceutical excellence.

EPISODE THREE 

Pharmacists play a vital role in supporting patients seeking acute, non-opioid pain relief, and their proactive engagement can ensure personalized and effective pain management solutions. Clinically proven, medicated patches deliver pain relief directly to the site of pain where it is needed most.  One effective prescription-strength option to consider is YARAL Pharma’s Diclofenac Epolamine Topical Patch 1.3%.  This option may be covered by the patient’s insurance; therefore, patients can access prescription-strength relief while minimizing out-of-pocket costs compared to over-the-counter alternatives.

Product Attributes:

Diclofenac epolamine topical system 1.3%: a nonsteroidal anti-inflammatory drug (NSAID) indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in adults and pediatric patients 6 years and older.

Accessible and Affordable
The Authorized Generic of the Flector® (diclofenac epolamine) topical system 1.3%. Patients receive a product identical to the brand, at an affordable price.

Targeted Topical Acute Pain Relief
Low systemic exposure. For a wide variety of patients and pain sites

Fast-acting
Significant pain relief within 4 hours after first application. Sustained pain reduction for 7 days with twice-a-day application

Long Lasting
Delivers NSAID power for 12 hours

Lidocaine Patch 5%: Treatment to help relieve pain associated with post-herpetic neuralgia, a complication from shingles, causing a burning painful skin rash.

ABOUT YARAL Pharma Inc. 

YARAL Pharma Inc. is the US subsidiary of IBSA, a global pharmaceutical company headquartered in Switzerland. By focusing on people and innovating the ways they’re cared for, YARAL Pharma is proud to offer the same values and expertise of its parent company to the US market.
Dedicated to ensuring access to affordable authorized generics (AGs) and complex generic medicines that enhance healthcare outcomes, YARAL Pharma offers its customers high-quality products across a range of therapeutic areas, continuity of supply, and a commitment to exceptional customer service.